Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
Suzette Girgis(Centre Hospitalier Universitaire de Nantes), Jenna D. Goldberg(Centre Hospitalier Universitaire de Nantes), Brandi Hilder(Sheba Medical Center), Damien Fink(Janssen (United States)), Shun Xin Wang Lin(Centre Hospitalier Universitaire de Nantes), Diego Vieyra(Janssen (United States)), Raluca Verona(Centre Hospitalier Universitaire de Nantes), Arnob Banerjee(Johnson & Johnson (United States)), Tara Stephenson(Centre Hospitalier Universitaire de Nantes), Jeffery S. Russell(University of Utah), Yang Chen(Janssen (United States)), Xin Miao(Johnson & Johnson (United States)), Jennifer Smit(Janssen (United States)), Jeffrey R. Infante(Cancer Research Center), Kodandaram Pillarisetti(Johnson & Johnson (United States)), Yusri Elsayed(Janssen (United States)), Tineke Casneuf(Argenx (Belgium))
Cited by 52
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k